Vehicle Topical Gel
Sponsors
Novan, Inc., Sun Pharmaceutical Industries, Inc., Aponia Laboratories, Inc., Maruho Co., Ltd., BioMendics, LLC
Conditions
Acne VulgarisActinic KeratosisCondylomata Acuminata (External)Cutaneous Common WartsDelayed Onset Muscle SorenessEpidermolysis Bullosa SimplexPainUsual Type Vulval Intraepithelial Neoplasia (uVIN)
Phase 1
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
CompletedNCT01694810
Start: 2012-09-30End: 2012-11-30Updated: 2020-01-30
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
CompletedNCT01742663
Start: 2012-10-31End: 2013-10-31Updated: 2014-01-22
Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex
CompletedNCT05062070
Start: 2022-05-05End: 2023-06-22Updated: 2023-09-11
Phase 2
Phase II Study of AP0302 5% Versus a Vehicle Comparator
CompletedNCT02324985
Start: 2015-01-31End: 2016-06-30Updated: 2019-02-25
A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris
CompletedNCT02571998
Start: 2015-10-31End: 2016-08-31Updated: 2017-03-27
Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN
CompletedNCT02596074
Start: 2015-11-30End: 2017-07-04Updated: 2017-08-03
Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts
CompletedNCT02849262
Start: 2016-07-31End: 2017-03-21Updated: 2017-03-31
Topical Ionic Contra-Viral Therapy in Actinic Keratosis
NCT03684772
Start: 2018-10-22End: 2019-09-30Target: 32Updated: 2019-05-01